DOCSLIB.ORG

Subunit Composition of the Mammalian Serine-Palmitoyltransferase Defines the Spectrum of Straight and Methyl-Branched Long-Chain Bases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subunit Composition of the Mammalian Serine-Palmitoyltransferase Defines the Spectrum of Straight and Methyl-Branched Long-Chain Bases Subunit composition of the mammalian serine-palmitoyltransferase defines the spectrum of straight and methyl-branched long-chain bases Museer A. Lonea,1, Andreas J. Hülsmeiera, Essa M. Saiedb,c, Gergely Karsaia, Christoph Arenzc, Arnold von Eckardsteina, and Thorsten Hornemanna,1 aInstitute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich-8091, Switzerland; bInstitute for Chemistry, Suez Canal University, Ismailia, Egypt; and cInstitute for Chemistry, Humboldt Universität zu Berlin, 12489 Berlin, Germany Edited by Howard Riezman, University of Geneva, Geneva, Switzerland, and accepted by Editorial Board Member David J. Mangelsdorf, May 20, 2020 (received for review February 11, 2020) Sphingolipids (SLs) are chemically diverse lipids that have impor- SPT activity is metabolically controlled by negative feedback tant structural and signaling functions within mammalian cells. SLs regulation. This mechanism is well understood in yeast, where are commonly defined by the presence of a long-chain base (LCB) SPT activity is regulated by two phosphoproteins, Orm1 and that is normally formed by the conjugation of L-serine and Orm2 (9, 10). Another protein, Tsc3, is required for maximal palmitoyl-CoA. This pyridoxal 5-phosphate (PLP)-dependent reac- SPT activation (11). SPT together with Orm1 and Orm2, Tsc3, tion is mediated by the enzyme serine-palmitoyltransferase (SPT). and the phosphoinositide phosphatase Sac1 form a multisubunit However, SPT can also metabolize other acyl-CoAs, in the range of complex (10). Orthologs of these proteins are also found in C14 to C18, forming a variety of LCBs that differ by structure and mammals, but their roles in regulating SL metabolism are less function. Mammalian SPT consists of three core subunits: SPTLC1, well understood. Mammalian cells express three ORM orthologs SPTLC2, and SPTLC3. Whereas SPTLC1 and SPTLC2 are ubiquitously (ORMDL1, 2, and 3) but lack the regulatory phosphorylation expressed, SPTLC3 expression is restricted to certain tissues only. sites of yeast Orm proteins (10, 12). The polypeptides ssSPTa The influence of the individual subunits on enzyme activity is not and ssSPTb are functional orthologs of Tsc3 that appear to clear. Using cell models deficient in SPTLC1, SPTLC2, and SPTLC3, modulate SPT activity and substrate affinity (13–15). While ssSPTa BIOCHEMISTRY we investigated the role of each subunit on enzyme activity and promotes canonical C18 LCB synthesis, ssSPTb is associated with the LCB product spectrum. We showed that SPTLC1 is essential for increased synthesis of C20 LCBs. In mice, a single gain-of-function activity, whereas SPTLC2 and SPTLC3 are partly redundant but mutation in ssSPTb (H56L) was shown to increase C20 LCB for- differ in their enzymatic properties. SPTLC1 in combination with mation in the brain, leading to retinopathy and central neuro- SPTLC2 specifically formed C18, C19, and C20 LCBs while the com- degeneration (14). However, the role of the individual SPT subunits bination of SPTLC1 and SPTLC3 yielded a broader product spec- trum. We identified anteiso-branched-C18 SO (meC18SO) as the with respect to SPT enzyme activity and substrate affinity has not primary product of the SPTLC3 reaction. The meC18SO was syn- yet been addressed systematically. thesized from anteiso-methyl-palmitate, in turn synthesized from In the present study, using SPTLC1-, SPTLC2-, and SPTLC3- a precursor metabolite generated in the isoleucine catabolic path- deficient cell models, we demonstrated that SPTLC1 is essential way. The meC18SO is metabolized to ceramides and complex SLs and is a constituent of human low- and high-density lipoproteins. Significance serine-palmitoyltransferase | long-chain base | omega-3-methyl- Sphingolipids (SLs) are complex lipids that constitute hundreds sphingosine of subspecies. All SLs share a long-chain base (LCB) as a de- fining structural component. LCBs are formed by serine- phingolipids (SLs) share the presence of a long-chain base palmitoyltransferase (SPT) in the first and rate-limiting step S(LCB) backbone as a common structural element. LCBs are of SL de novo synthesis. SPT consists of three subunits that show aliphatic amino alcohols and formed in the first and rate-limiting tissue-specific expression. In presence of the SPTLC3 subunit, the step of SL de novo synthesis (SI Appendix, Fig. S1). This reaction enzyme forms a spectrum of straight and branched LCBs with is catalyzed by the enzyme serine-palmitoyltransferase (SPT). distinct biochemical and biophysical properties. This alters the composition of cellular membranes and might influence the SPT is a pyridoxal 5‐phosphate (PLP)-dependent α‐oxoamino- dynamics of membrane-related transport and signaling events. transferase that consists of three core subunits—SPTLC1, SPTLC2, — SPTLC3 is particularly abundant in skin, and changes in SPT ac- and SPTLC3 that share a mutual homology. SPTLC2 is 68% tivity are related to dermal pathologies. Genetic variants of identical to SPTLC3 (84% similarity), whereas SPTLC1 is more SPTLC3 are associated with metabolic conditions such as distinct, sharing ∼21% identity (45% similarity) with SPTLC2 and dyslipidemia and atherosclerosis. SPTLC3 (1). The PLP-binding motif is present in SPTLC2 and SPTLC3 but not in SPTLC1. While SPTLC1 and SPTLC2 are Author contributions: M.A.L. and T.H. designed research; M.A.L., A.J.H., and G.K. per- ubiquitously expressed, SPTLC3 expression is restricted to specific formed research; E.M.S. and C.A. contributed new reagents/analytic tools; M.A.L., A.J.H., and G.K. analyzed data; and M.A.L., A.v.E., and T.H. wrote the paper. tissues, such as placenta, skin, and some glands (2–6). LCBs vary structurally within and across species. In mammals, The authors declare no competing interest. the most abundant LCB is sphingosine (SO; d18:1), which repre- This article is a PNAS Direct Submission. H.R. is a guest editor invited by the Editorial Board. sents ∼60% of the total LCBs in human plasma (7). The remaining Published under the PNAS license. LCBs differ with respect to chain length, desaturation, and hy- 1To whom correspondence may be addressed. Email: [email protected] or droxylation (reviewed in ref. 8). Plants and fungi, including yeast, [email protected]. mostly form phytosphingosine (phytoSO; t18:0), which is also pre- This article contains supporting information online at https://www.pnas.org/lookup/suppl/ sent at low levels in humans. Insects mainly form short-chain LCBs doi:10.1073/pnas.2002391117/-/DCSupplemental. in the range of C14 to C16 (8). www.pnas.org/cgi/doi/10.1073/pnas.2002391117 PNAS Latest Articles | 1of8 Downloaded by guest on October 4, 2021 for formation of an active enzyme. In contrast, SPTLC2 and the absence of SPTLC1, we observed a concomitant loss of SPTLC3 are partly redundant but differ in function and substrate SPTLC2, whereas deletion of SPTLC2 did not influence SPTLC1 specificity. Furthermore, we identified a novel, methyl-branched levels (Fig. 1A). This suggested that SPTLC2 is unstable in the LCB as a specific product of human SPTLC3. Methyl-branched absence of SPTLC1, whereas SPTLC1 is stable on its own. LCBs are the major forms in lower invertebrates, such as Cae- Next, SPT activity was measured by the time-dependent in- 15 norhabditis elegans (16), but have not been reported in humans corporation of isotope-labeled L-serine (2,3,3-D3, N) into the until now. de novo formed LCBs. As one of the deuteriums is lost during the conjugation reaction (18), the de novo synthesized LCBs had Results an additional mass of +3 Da. In HAP1 wild-type (WT) cells, we SPTLC1 Is Indispensable for De Novo SPT Function. To investigate the observed a significant formation of C18SO+3, which was com- role of individual subunits on SPT activity, we generated SPTLC1 pletely abrogated in the absence of either SPTLC1 or SPTLC2 and SPTLC2 knockout (KO) HAP1 cell lines using a CRISPR/ (Fig. 1B). Reconstitution of SPTLC1 and STPLC2 expression in Cas9 approach. HAP1 cells are haploid and derived from chronic the respective null background restored enzyme activity (Fig. myelogenous leukemia (CML) cells (17). Natively, HAP1 cells 1C). SPTLC1 expression in the SPTLC1 KO cells rescued en- express SPTLC1 and SPTLC2 but not SPTLC3 (SI Appendix, Fig. dogenous SPTLC2 expression (Fig. 1D). Expression of SPTLC3 S2A). The CRISPR/Cas9 induced loss of SPTLC1 and SPTLC2 in the absence of SPTLC2 resulted in an active SPT enzyme but was confirmed by Western blot analysis (Fig. 1A). Surprisingly, in with significantly lower formation of C18SO+3 compared with C18SO C18SA A B 120 SPTLC2 + + - SPTLC1 + - + [kDa] 80 100 Calnexin 70 HAP1 cells SPTLC1 55 40 70 nd SPTLC2 55 pmoles/10 0 SPTLC1 + + - + SPTLC2 + + + - Myriocin - + - - C D WT SPTLC1 KO 100 C18SO C18SA ** Vector + + - - - SPTLC1-V5 - - + - - SPTLC2-V5 - - - + - SPTLC3-V5 - - - - + [kDa] 100 HAP1 cells Calnexin 50 70 70 Anti-V5 55 70 nd SPTLC1 55 nd pmoles/10 70 0 SPTLC2 Vector + - - - - + - - - 55 SPTLC1 - + - - - - + - - SPTLC2 - - + - + - - + - SPTLC3 - - - + + - - - + SPTLC1 KO SPTLC2 KO E F IP V5-tag IP V5-tag 1.5 Vector + - - - + - - - C16SO SPTLC1-V5 - + - - - + - - SPTLC2-V5 C17SO - - + - - - + - C19SO SPTLC3-V5 - - - + - - - + [kDa] 1.0 70 C20SO Anti-V5 55 HAP1 cells SPTLC1 55 0.5 70 SPTLC2 55 nd ndnd pmoles/10 0 Wild type SPTLC2 KO Vector SPTLC2 SPTLC3 Fig. 1. SPT composition and activity in SPTLC1- and SPTLC2-deficient HAP1 cells. (A) Western blot showing CRISPR/Cas9-mediated loss of SPTLC1 and SPTLC2 expression in the respective HAP1 KO lines. The loss of SPTLC1 led to a concomitant loss of SPTLC2 expression. Calnexin served as a loading control. (B) SPT 15 activity in SPTLC1- and SPTLC2-2 deficient cells compared with HAP1 WT cells. SPT activity was measured by the incorporation of (2,3,3-D3, N)-L-serine into de novo formed LCBs. One deuterium is lost during the conjugation reaction, which results in a mass shift of +3 Da for the de novo formed LCBs. No LCBs were formed in presence of the SPT inhibitor myriocin.
Load more

Recommended publications
  • Retinamide Increases Dihydroceramide and Synergizes with Dimethylsphingosine to Enhance Cancer Cell Killing
    2967 N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing Hongtao Wang,1 Barry J. Maurer,1 Yong-Yu Liu,2 elevations in dihydroceramides (N-acylsphinganines), Elaine Wang,3 Jeremy C. Allegood,3 Samuel Kelly,3 but not desaturated ceramides, and large increases in Holly Symolon,3 Ying Liu,3 Alfred H. Merrill, Jr.,3 complex dihydrosphingolipids (dihydrosphingomyelins, Vale´rie Gouaze´-Andersson,4 Jing Yuan Yu,4 monohexosyldihydroceramides), sphinganine, and sphin- Armando E. Giuliano,4 and Myles C. Cabot4 ganine 1-phosphate. To test the hypothesis that elevation of sphinganine participates in the cytotoxicity of 4-HPR, 1Childrens Hospital Los Angeles, Keck School of Medicine, cells were treated with the sphingosine kinase inhibitor University of Southern California, Los Angeles, California; D-erythro-N,N-dimethylsphingosine (DMS), with and 2 College of Pharmacy, University of Louisiana at Monroe, without 4-HPR. After 24 h, the 4-HPR/DMS combination Monroe, Louisiana; 3School of Biology and Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, caused a 9-fold increase in sphinganine that was sustained Atlanta, Georgia; and 4Gonda (Goldschmied) Research through +48 hours, decreased sphinganine 1-phosphate, Laboratories at the John Wayne Cancer Institute, and increased cytotoxicity. Increased dihydrosphingolipids Saint John’s Health Center, Santa Monica, California and sphinganine were also found in HL-60 leukemia cells and HT-29 colon cancer cells treated with 4-HPR. The Abstract 4-HPR/DMS combination elicited increased apoptosis in all three cell lines. We propose that a mechanism of N Fenretinide [ -(4-hydroxyphenyl)retinamide (4-HPR)] is 4-HPR–induced cytotoxicity involves increases in dihy- cytotoxic in many cancer cell types.
    [Show full text]
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • (4,5) Bisphosphate-Phospholipase C Resynthesis Cycle: Pitps Bridge the ER-PM GAP
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Topological organisation of the phosphatidylinositol (4,5) bisphosphate-phospholipase C resynthesis cycle: PITPs bridge the ER-PM GAP Shamshad Cockcroft and Padinjat Raghu* Dept. of Neuroscience, Physiology and Pharmacology, Division of Biosciences, University College London, London WC1E 6JJ, UK; *National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India Address correspondence to: Shamshad Cockcroft, University College London UK; Phone: 0044-20-7679-6259; Email: [email protected] Abstract Phospholipase C (PLC) is a receptor-regulated enzyme that hydrolyses phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) at the plasma membrane (PM) triggering three biochemical consequences, the generation of soluble inositol 1,4,5-trisphosphate (IP3), membrane– associated diacylglycerol (DG) and the consumption of plasma membrane PI(4,5)P2. Each of these three signals triggers multiple molecular processes impacting key cellular properties. The activation of PLC also triggers a sequence of biochemical reactions, collectively referred to as the PI(4,5)P2 cycle that culminates in the resynthesis of this lipid. The biochemical intermediates of this cycle and the enzymes that mediate these reactions are topologically distributed across two membrane compartments, the PM and the endoplasmic reticulum (ER). At the plasma membrane, the DG formed during PLC activation is rapidly converted to phosphatidic acid (PA) that needs to be transported to the ER where the machinery for its conversion into PI is localised. Conversely, PI from the ER needs to be rapidly transferred to the plasma membrane where it can be phosphorylated by lipid kinases to regenerate PI(4,5)P2.
    [Show full text]
  • Antibacterial Activity of Ceramide and Ceramide Analogs Against
    www.nature.com/scientificreports OPEN Antibacterial activity of ceramide and ceramide analogs against pathogenic Neisseria Received: 10 August 2017 Jérôme Becam1, Tim Walter 2, Anne Burgert3, Jan Schlegel 3, Markus Sauer3, Accepted: 1 December 2017 Jürgen Seibel2 & Alexandra Schubert-Unkmeir1 Published: xx xx xxxx Certain fatty acids and sphingoid bases found at mucosal surfaces are known to have antibacterial activity and are thought to play a more direct role in innate immunity against bacterial infections. Herein, we analysed the antibacterial activity of sphingolipids, including the sphingoid base sphingosine as well as short-chain C6 and long-chain C16-ceramides and azido-functionalized ceramide analogs against pathogenic Neisseriae. Determination of the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) demonstrated that short-chain ceramides and a ω-azido- functionalized C6-ceramide were active against Neisseria meningitidis and N. gonorrhoeae, whereas they were inactive against Escherichia coli and Staphylococcus aureus. Kinetic assays showed that killing of N. meningitidis occurred within 2 h with ω–azido-C6-ceramide at 1 X the MIC. Of note, at a bactericidal concentration, ω–azido-C6-ceramide had no signifcant toxic efect on host cells. Moreover, lipid uptake and localization was studied by fow cytometry and confocal laser scanning microscopy (CLSM) and revealed a rapid uptake by bacteria within 5 min. CLSM and super-resolution fuorescence imaging by direct stochastic optical reconstruction microscopy demonstrated homogeneous distribution of ceramide analogs in the bacterial membrane. Taken together, these data demonstrate the potent bactericidal activity of sphingosine and synthetic short-chain ceramide analogs against pathogenic Neisseriae. Sphingolipids are composed of a structurally related family of backbones termed sphingoid bases, which are sometimes referred to as ‘long-chain bases’ or ‘sphingosines’.
    [Show full text]
  • The Modulation of Sphingolipids by Human Cytomegalovirus and Its Influence on Viral Protein Accumulation and Growth
    THE MODULATION OF SPHINGOLIPIDS BY HUMAN CYTOMEGALOVIRUS AND ITS INFLUENCE ON VIRAL PROTEIN ACCUMULATION AND GROWTH DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Nicholas John Machesky, B.S. ***** The Ohio State University 2007 Dissertation Committee: Approved by Professor James R. Van Brocklyn, Advisor Professor Joanne Trgovcich _________________________________ Professor W. James Waldman Advisor Integrated Biomedical Science Graduate Program Professor Chien-Liang Lin ABSTRACT Human cytomegalovirus (HCMV) is a β-herpes virus which can cause serious disease and even death in congenitally-infected infants and in immunocompromised individuals or immunosuppressed transplant recipients. This virus promotes its own replication by exploiting many cellular signaling pathways. Sphingolipids are structural components of cell membranes which can act as critical mediators of cell signaling. Sphingosine kinase (SphK) can phosphorylate dihydrosphingosine (dhSph) and sphingosine (Sph) to produce dihydrosphingosine-1-phosphate (dhS1P) and sphingosine- 1-phosphate (S1P), respectively, which can activate many signaling pathways through binding to G-protein coupled S1P receptors, named S1P1-5. An area of research which has yet to be elucidated is whether HCMV modulates sphingolipids and their signaling pathways. Our data show that HCMV infection results in increased accumulation and activity of sphingosine kinase (SphK) within different cell types. This occurs during early times of infection in that it occurs after virus entry but before replication of viral DNA. Measuring the levels of transcripts encoding key enzymes of the sphingolipid metabolic pathway during HCMV infection revealed a temporal regulation of both synthetic and degradative enzymes of this pathway.
    [Show full text]
  • Role of Phospholipases in Adrenal Steroidogenesis
    229 1 W B BOLLAG Phospholipases in adrenal 229:1 R29–R41 Review steroidogenesis Role of phospholipases in adrenal steroidogenesis Wendy B Bollag Correspondence should be addressed Charlie Norwood VA Medical Center, One Freedom Way, Augusta, GA, USA to W B Bollag Department of Physiology, Medical College of Georgia, Augusta University (formerly Georgia Regents Email University), Augusta, GA, USA [email protected] Abstract Phospholipases are lipid-metabolizing enzymes that hydrolyze phospholipids. In some Key Words cases, their activity results in remodeling of lipids and/or allows the synthesis of other f adrenal cortex lipids. In other cases, however, and of interest to the topic of adrenal steroidogenesis, f angiotensin phospholipases produce second messengers that modify the function of a cell. In this f intracellular signaling review, the enzymatic reactions, products, and effectors of three phospholipases, f phospholipids phospholipase C, phospholipase D, and phospholipase A2, are discussed. Although f signal transduction much data have been obtained concerning the role of phospholipases C and D in regulating adrenal steroid hormone production, there are still many gaps in our knowledge. Furthermore, little is known about the involvement of phospholipase A2, Endocrinology perhaps, in part, because this enzyme comprises a large family of related enzymes of that are differentially regulated and with different functions. This review presents the evidence supporting the role of each of these phospholipases in steroidogenesis in the Journal Journal of Endocrinology adrenal cortex. (2016) 229, R1–R13 Introduction associated GTP-binding protein exchanges a bound GDP for a GTP. The G protein with GTP bound can then Phospholipids serve a structural function in the cell in that activate the enzyme, phospholipase C (PLC), that cleaves they form the lipid bilayer that maintains cell integrity.
    [Show full text]
  • SPTLC2 Polyclonal Antibody
    SPTLC2 polyclonal antibody It catalyzes the pyridoxal-5-prime-phosphate-dependent condensation of L-serine and palmitoyl-CoA to Catalog Number: PAB4377 3-oxosphinganine. Mutations in this gene were identified in patients with hereditary sensory neuropathy type I. Regulatory Status: For research use only (RUO) Alternatively spliced variants encoding different isoforms have been identified. [provided by RefSeq] Product Description: Rabbit polyclonal antibody raised against synthetic peptide of SPTLC2. References: 1. Permeability barrier disruption increases the level of Immunogen: A synthetic peptide (conjugated with KLH) serine palmitoyltransferase in human epidermis. corresponding to amino acids 532-562 of human Stachowitz S, Alessandrini F, Abeck D, Ring J, Behrendt SPTLC2. H. J Invest Dermatol. 2002 Nov;119(5):1048-52. 2. Shotgun sequencing of the human transcriptome with Host: Rabbit ORF expressed sequence tags. Dias Neto E, Correa RG, Verjovski-Almeida S, Briones MR, Nagai MA, da Reactivity: Human,Mouse Silva W Jr, Zago MA, Bordin S, Costa FF, Goldman GH, Applications: ELISA, WB-Ti Carvalho AF, Matsukuma A, Baia GS, Simpson DH, (See our web site product page for detailed applications Brunstein A, de Oliveira PS, Bucher P, Jongeneel CV, information) O'Hare MJ, Soares F, Brentani RR, Reis LF, de Souza SJ, Simpson AJ. Proc Natl Acad Sci U S A. 2000 Mar Protocols: See our web site at 28;97(7):3491-6. http://www.abnova.com/support/protocols.asp or product 3. Human and murine serine-palmitoyl-CoA page for detailed protocols transferase--cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Weiss B, Form: Liquid Stoffel W.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • STA-601-Sphingomyelin-Assay-Kit.Pdf
    Introduction Phospholipids are important structural lipids that are the major component of cell membranes and lipid bilayers. Phospholipids contain a hydrophilic head and a hydrophobic tail which give the molecules their unique characteristics. Most phospholipids contain one diglyceride, a phosphate group, and one choline group. Sphingomyelin (ceramide phosphorylcholine) is a sphingolipid found in eukaryotic cell membranes and lipoproteins. Sphingomyelin usually consists of a ceramide and phosphorylcholine molecule where the ceramide core comprises of a fatty acid bonded via an amide bond to a sphingosine molecule. There is a polar head group which is either phosphphoethanolamine or phosphocholine. Sphingomyelin represents about 85% of all sphingolipids and makes up about 10-20% of lipids within the plasma membrane. Sphingomyelin is involved in signal transduction and is highly concentrated in the myelin sheath around many nerve cell axons. The plasma membranes of many cells are rich with sphingomyelin. Sphigolipids are synthesized in a pathway that originates in the ER and is completed in the Golgi apparatus. Many of their functions are done in the plasma membranes and endosomes. Sphingomyelin is converted to ceramide via sphingomyelinases. Ceramides have been implicated in signaling pathways that lead to apoptosis, differentiation and proliferation. Sphingomyelins have been implicated in the pathogenesis of atherosclerosis, inflammation, necrosis, autophagy, senescence, stress response as well as other signaling disease states. Niemann-Pick disease is an inherited disease where deficiency of sphingomyelinase activity results in sphingomyelin accumulating in cells, tissues, and fluids. Other sphingolipid diseases are Fabry disease, Gaucher disease, Tay-Sachs disease, Krabbe disease and Metachromatic leukodystrophy. Cell Biolabs’ Sphingomyelin Assay Kit is a simple fluorometric assay that measures the amount of sphingomyelin present in plasma or serum, tissue homogenates, or cell suspensions in a 96-well microtiter plate format.
    [Show full text]
  • Neurological S1P Signaling As an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis
    Arch Pharm Res Vol 33, No 10, 1567-1574, 2010 DOI 10.1007/s12272-010-1008-5 REVIEW Neurological S1P Signaling as an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis Chang Wook Lee1, Ji Woong Choi2, and Jerold Chun1 1Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, California 92037, USA and 2Department of Pharmacology, Division of Basic Medicine and Science, Gachon University of Medi- cine and Science, Incheon 406-799, Korea (Received August 15, 2010/Revised August 23, 2010/Accepted August 24, 2010) FTY720 (fingolimod, Novartis) is a promising investigational drug for relapsing forms of multi- ple sclerosis (MS), an autoimmune and neurodegenerative disorder of the central nervous sys- tem. It is currently under FDA review in the United States, and could represent the first approved oral treatment for MS. Extensive, ongoing clinical trials in Phase II/III have sup- ported both the efficacy and safety of FTY720. FTY720 itself is not bioactive, but when phospho- rylated (FTY720-P) by sphingosine kinase 2, it becomes active through modulation of 4 of the 5 known G protein-coupled sphingosine 1-phosphate (S1P) receptors. The mechanism of action (MOA) is thought to be immunological, where FTY720 alters lymphocyte trafficking via S1P1. However, MOA for FTY720 in MS may also involve a direct, neurological action within the cen- tral nervous system in view of documented S1P receptor-mediated signaling influences in the brain, and this review considers observations that support an emerging neurological MOA. Key words: FTY720, Fingolimod, Sphingosine 1-phosphate receptors, Multiple sclerosis, Cen- tral nervous system INTRODUCTION factors that initiate MS are still unknown.
    [Show full text]
  • IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model
    IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model Andrea Chiricozzi1,2,3*, Kristine E. Nograles1,2, Leanne M. Johnson-Huang1, Judilyn Fuentes-Duculan1, Irma Cardinale1, Kathleen M. Bonifacio1, Nicholas Gulati1, Hiroshi Mitsui1, Emma Guttman-Yassky1,2,4, Mayte Sua´rez-Farin˜ as1,2", James G. Krueger1,2" 1 Laboratory for Investigative Dermatology, The Rockefeller University, New York City, New York, United States of America, 2 Center for Clinical and Translational Science, The Rockefeller University, New York City, New York, United States of America, 3 Department of Dermatology, University of Rome ‘‘Tor Vergata’’, Rome, Italy, 4 Department of Dermatology, Mount Sinai School of Medicine, New York City, New York, United States of America Abstract Background: IL-17 is the defining cytokine of the Th17, Tc17, and cd T cell populations that plays a critical role in mediating inflammation and autoimmunity. Psoriasis vulgaris is an inflammatory skin disease mediated by Th1 and Th17 cytokines with relevant contributions of IFN-c, TNF-a, and IL-17. Despite the pivotal role IL-17 plays in psoriasis, and in contrast to the other key mediators involved in the psoriasis cytokine cascade that are capable of inducing broad effects on keratinocytes, IL-17 was demonstrated to regulate the expression of a limited number of genes in monolayer keratinocytes cultured in vitro. Methodology/Principal Findings: Given the clinical efficacy of anti-IL-17 agents is associated with an impressive reduction in a large set of inflammatory genes, we sought a full-thickness skin model that more closely resemble in vivo epidermal architecture.
    [Show full text]